was read the article
array:24 [ "pii" => "S1665268119309299" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)30929-9" "estado" => "S300" "fechaPublicacion" => "2012-05-01" "aid" => "70685" "copyright" => "Fundación Clínica Médica Sur, A.C." "copyrightAnyo" => "2012" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2012;11:338-42" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 64 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 23 "PDF" => 35 ] ] "itemSiguiente" => array:19 [ "pii" => "S1665268119309305" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)30930-5" "estado" => "S300" "fechaPublicacion" => "2012-05-01" "aid" => "70686" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2012;11:343-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 86 "formatos" => array:3 [ "EPUB" => 8 "HTML" => 37 "PDF" => 41 ] ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Serum adipocyte fatty acid binding protein in liver transplant recipients and the metabolic syndrome" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "343" "paginaFinal" => "349" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "f0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 661 "Ancho" => 1004 "Tamanyo" => 32784 ] ] "descripcion" => array:1 [ "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Serum AFABP4 levels in liver transplanted patients according to the presence of metabolic syndrome.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Hemda Schmilovitz-Weiss, Ido Laish, Zohar Levi, Yehudith Monsselise, Yael Harif, Marius Braun, Mona Boaz, Ziv Ben Ari" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Hemda" "apellidos" => "Schmilovitz-Weiss" ] 1 => array:2 [ "nombre" => "Ido" "apellidos" => "Laish" ] 2 => array:2 [ "nombre" => "Zohar" "apellidos" => "Levi" ] 3 => array:2 [ "nombre" => "Yehudith" "apellidos" => "Monsselise" ] 4 => array:2 [ "nombre" => "Yael" "apellidos" => "Harif" ] 5 => array:2 [ "nombre" => "Marius" "apellidos" => "Braun" ] 6 => array:2 [ "nombre" => "Mona" "apellidos" => "Boaz" ] 7 => array:2 [ "nombre" => "Ziv Ben" "apellidos" => "Ari" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119309305?idApp=UINPBA00004N" "url" => "/16652681/0000001100000003/v1_201906130956/S1665268119309305/v1_201906130956/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1665268119309287" "issn" => "16652681" "doi" => "10.1016/S1665-2681(19)30928-7" "estado" => "S300" "fechaPublicacion" => "2012-05-01" "aid" => "70684" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Ann Hepatol. 2012;11:330-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 75 "formatos" => array:3 [ "EPUB" => 7 "HTML" => 21 "PDF" => 47 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Hepatitis B virus prevalence and vaccination response in health care workers and students at the Federal University of Bahia, Brazil" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "330" "paginaFinal" => "337" ] ] "contieneResumen" => array:1 [ "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Patrícia Carvalho, Maria Isabel Schinoni, Jacy Andrade, Marco Antonio Vasconcelos Rêgo, Patricia Marques, Roberto Meyer, Alex Araújo, Thomaz Menezes, Carolina Oliveira, Rodrigo Sousa Macêdo, Lucas Sousa Macédo, Júlio César Leal, Betânia Matos, Robert Schaer, Jucara M. Simões, Songeli M. Freire, Raymundo Paraná" "autores" => array:17 [ 0 => array:2 [ "nombre" => "Patrícia" "apellidos" => "Carvalho" ] 1 => array:2 [ "nombre" => "Maria" "apellidos" => "Isabel Schinoni" ] 2 => array:2 [ "nombre" => "Jacy" "apellidos" => "Andrade" ] 3 => array:2 [ "nombre" => "Marco Antonio" "apellidos" => "Vasconcelos Rêgo" ] 4 => array:2 [ "nombre" => "Patricia" "apellidos" => "Marques" ] 5 => array:2 [ "nombre" => "Roberto" "apellidos" => "Meyer" ] 6 => array:2 [ "nombre" => "Alex" "apellidos" => "Araújo" ] 7 => array:2 [ "nombre" => "Thomaz" "apellidos" => "Menezes" ] 8 => array:2 [ "nombre" => "Carolina" "apellidos" => "Oliveira" ] 9 => array:2 [ "nombre" => "Rodrigo" "apellidos" => "Sousa Macêdo" ] 10 => array:2 [ "nombre" => "Lucas" "apellidos" => "Sousa Macédo" ] 11 => array:2 [ "nombre" => "Júlio" "apellidos" => "César Leal" ] 12 => array:2 [ "nombre" => "Betânia" "apellidos" => "Matos" ] 13 => array:2 [ "nombre" => "Robert" "apellidos" => "Schaer" ] 14 => array:2 [ "nombre" => "Jucara M." "apellidos" => "Simões" ] 15 => array:2 [ "nombre" => "Songeli M." "apellidos" => "Freire" ] 16 => array:2 [ "nombre" => "Raymundo" "apellidos" => "Paraná" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119309287?idApp=UINPBA00004N" "url" => "/16652681/0000001100000003/v1_201906130956/S1665268119309287/v1_201906130956/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "338" "paginaFinal" => "342" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Francesca Romana Ponziani, Alessandro Milani, Antonio Gasbarrini, Raffaella Zaccaria, Raffaella Viganò, Maria Francesca Donato, Maria Cristina Morelli, Lucia Miglioresi, Luisa Pasulo, Maria Rendina, Daniele Di Paolo, Maria Marino, Pierluigi Toniutto, Stefano Fagiuoli, Maurizio Pompili" "autores" => array:15 [ 0 => array:4 [ "nombre" => "Francesca" "apellidos" => "Romana Ponziani" "email" => array:1 [ 0 => "francesca.ponziani@yahoo.it" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor1" ] ] ] 1 => array:3 [ "nombre" => "Alessandro" "apellidos" => "Milani" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] ] ] 2 => array:3 [ "nombre" => "Antonio" "apellidos" => "Gasbarrini" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] ] ] 3 => array:3 [ "nombre" => "Raffaella" "apellidos" => "Zaccaria" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] ] ] 4 => array:3 [ "nombre" => "Raffaella" "apellidos" => "Viganò" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">†</span>" "identificador" => "aff2" ] ] ] 5 => array:3 [ "nombre" => "Maria" "apellidos" => "Francesca Donato" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">‡</span>" "identificador" => "aff3" ] ] ] 6 => array:3 [ "nombre" => "Maria" "apellidos" => "Cristina Morelli" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">§</span>" "identificador" => "aff4" ] ] ] 7 => array:3 [ "nombre" => "Lucia" "apellidos" => "Miglioresi" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">||</span>" "identificador" => "aff5" ] ] ] 8 => array:3 [ "nombre" => "Luisa" "apellidos" => "Pasulo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¶</span>" "identificador" => "aff6" ] ] ] 9 => array:3 [ "nombre" => "Maria" "apellidos" => "Rendina" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "**" "identificador" => "aff7" ] ] ] 10 => array:3 [ "nombre" => "Daniele" "apellidos" => "Di Paolo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">††</span>" "identificador" => "aff8" ] ] ] 11 => array:3 [ "nombre" => "Maria" "apellidos" => "Marino" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">‡‡</span>" "identificador" => "aff9" ] ] ] 12 => array:3 [ "nombre" => "Pierluigi" "apellidos" => "Toniutto" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">§§</span>" "identificador" => "aff10" ] ] ] 13 => array:3 [ "nombre" => "Stefano" "apellidos" => "Fagiuoli" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¶</span>" "identificador" => "aff6" ] ] ] 14 => array:3 [ "nombre" => "Maurizio" "apellidos" => "Pompili" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "aff1" ] ] ] ] "afiliaciones" => array:10 [ 0 => array:3 [ "entidad" => "AISF RECOLT-C group: *Catholic University of Rome. Italy" "etiqueta" => "*" "identificador" => "aff1" ] 1 => array:3 [ "entidad" => "Niguarda Ca’ Granda Hospital. Italy" "etiqueta" => "†" "identificador" => "aff2" ] 2 => array:3 [ "entidad" => "Policlinico of Milan. Italy" "etiqueta" => "‡" "identificador" => "aff3" ] 3 => array:3 [ "entidad" => "Sant’Orsola Malpighi Hospital. Italy" "etiqueta" => "©" "identificador" => "aff4" ] 4 => array:3 [ "entidad" => "S. Camillo-Spallanzani Hospital. Italy" "etiqueta" => "||" "identificador" => "aff5" ] 5 => array:3 [ "entidad" => "Ospedali Riuniti of Bergamo. Italy" "etiqueta" => "¶" "identificador" => "aff6" ] 6 => array:3 [ "entidad" => "University of Bari. Italy" "etiqueta" => "**" "identificador" => "aff7" ] 7 => array:3 [ "entidad" => "University of Rome Torvergata. Italy" "etiqueta" => "††" "identificador" => "aff8" ] 8 => array:3 [ "entidad" => "University of Modena. Italy" "etiqueta" => "‡‡" "identificador" => "aff9" ] 9 => array:3 [ "entidad" => "University of Udine. Italy" "etiqueta" => "©©" "identificador" => "aff10" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "*" "correspondencia" => "Correspondence and reprint request:" ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Introduction</span><p id="p0005" class="elsevierStylePara elsevierViewall">Hepatitis C virus (HCV) has 6 major genotypes and over 76 subtypes.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> Genotype 4 is widely prevalent in the Middle East and Northern Africa and is predominant in Egypt, where accounts for more than 90% of HCV infections.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Genotype 4 HCV infection has a low prevalence in Europe, ranging between 0 and 19%, even if, in Mediterranean countries such as France, Spain, Greece and Italy, a trend towards an increasing prevalence has been recently observed.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> The main reasons for this phenomenon appear to be the increased immigration from high prevalence areas and the diffusion among intravenous drug abusers.</p><p id="p0010" class="elsevierStylePara elsevierViewall">Early reports have shown that patients with genotype 4 chronic hepatitis C respond as poorly as those with genotype 1 to conventional interferon (IFN) alpha and to combined IFN alpha plus ribavirin therapy.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7</span></a><span class="elsevierStyleSup">–</span><a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> More recently, a few trials on the treatment of genotype 4 chronic hepatitis C using pegylated (PEG) IFN alpha 2b or alpha 2a plus ribavirin have been published, reporting highly variable rates of sustained virological response (SVR), ranging from 33 to 69%.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11</span></a><span class="elsevierStyleSup">–</span><a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> On the whole, the SVR rate of patients with chronic genotype 4 hepatitis C treated with PEG-IFN plus ribavirin seems to be slightly higher than that observed for genotype 1 (42-46%), but lower than that observed for genotypes 2 and 3 (76-82%).<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> Furthermore, recent data suggest that, in genotype 4 patients, the achievement of a rapid virological response (RVR).<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> or an early virological response (EVR)<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> may be highly predictive of a subsequent SVR; moreover, a higher SVR rate can be observed in Egyptian patients compared to matched European patients.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="p0015" class="elsevierStylePara elsevierViewall">Only a few data about the clinical course and the treatment outcome of patients with genotype 4 chronic hepatitis C recurrence after liver transplantation (LT) are still currently available, especially in Europe.</p><p id="p0020" class="elsevierStylePara elsevierViewall">The aim of this study is to retrospectively evaluate the effectiveness of the antiviral treatment in an Italian multicentric cohort of patients with genotype 4 chronic hepatitis C recurrence after LT.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Material and Methods</span><p id="p0025" class="elsevierStylePara elsevierViewall">Seventeen patients (16 males and 1 female) aged from 39 to 59 years and affected by genotype 4-related chronic hepatitis C recurrence after LT were enrolled in the study. Five of them were native to Egypt, the remainders were Caucasian. All patients were followed-up in 9 Italian Transplant centres, during the period 1996-2010; and the time between LT and the clinical recurrence of hepatitis C ranged from 4 to 67 weeks (mean 25.1 weeks). None of the investigated patients had experienced a pre-LT treatment for HCV infection.</p><p id="p0030" class="elsevierStylePara elsevierViewall">The outstanding clinical characteristics of the investigated patients are summarized in <a class="elsevierStyleCrossRef" href="#t0005">table 1</a>.</p><elsevierMultimedia ident="t0005"></elsevierMultimedia><p id="p0035" class="elsevierStylePara elsevierViewall">The quantitative value of pre-treatment HCVRNA was available in 14 out of 17 patients (mean viremia 2.423.235 IU/mL, range 234-7.692.307 IU/mL), and a high viral load (more than 600.000 IU/mL) was detected in 7/14 cases. In the remaining 3 patients, transplanted before 2000, only a positivity for serum HCV-RNA was available.</p><p id="p0040" class="elsevierStylePara elsevierViewall">Hepatocellular carcinoma (HCC) before LT was diagnosed in five patients (29.4%).</p><p id="p0045" class="elsevierStylePara elsevierViewall">Patients were treated with conventional doses of recombinant (2 cases) or PEG-IFN (15 cases) alpha plus ribavirin for a scheduled period of 48-weeks.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results</span><p id="p0050" class="elsevierStylePara elsevierViewall">The main results of the study are shown in <a class="elsevierStyleCrossRef" href="#t0005">table 1</a>. We did not find any significant difference in the immunosoppressive regimen scheduled for these patients, since 8 received cyclosporine, 8 tacrolimus and 1 rapamcycine as the main immunosuppressive agent. The mean donor age was 46.6 (16-86 yrs); donors were 9 males and 8 of females; a donor-recipient gender mismatch was present in 7 case, always of the type female donor in male recipient.</p><p id="p0055" class="elsevierStylePara elsevierViewall">Antiviral treatment duration was of at least 24 weeks in 14 subjects (82.3%), and 8 of them (47%) completed a standard 48-week course of treatment. Three patients received less than 24 weeks of antiviral treatment; in particular, patient n. 4 withdrew the treatment at week 16 for urgent abdominal surgery due to laparocele, while patients n. 6 and n. 15 suspended the treatment after 12 weeks for personal choice and for severe anemia, respectively. Six patients withdrew the treatment after 24 weeks, for the occurrence of neuropsychiatric symptoms, severe neutropenia, cholangitis, hepatocellular carcinoma recurrence and, finally, in two cases, lack of virological response.</p><p id="p0060" class="elsevierStylePara elsevierViewall">A SVR was achieved in more than one third (35.3%) of the investigated patients, with a negative HCV-RNA persisting for at least 3 years (long term response) in all of them.</p><p id="p0065" class="elsevierStylePara elsevierViewall">An EVR was achieved in 7 out of the 17 patients (41.1%). In the 14 patients who completed at least 24 weeks of treatment, we could also assess the ability of EVR in predicting the occurrence of SVR; 80% (4/5) of the patients exhibiting an EVR achieved a SVR, while it occurred in only one patient without EVR. In this way, EVR was significantly associated with the occurrence of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square p < 0.05).</p><p id="p0070" class="elsevierStylePara elsevierViewall">Interestingly, one of the 3 patients who did not complete a 24-week course of treatment (<a class="elsevierStyleCrossRef" href="#t0005">Table 1</a>, patient n. 6), achieved an EVR together with a SVR.</p><p id="p0075" class="elsevierStylePara elsevierViewall">The observed overall survival rates (Kaplan-Meier method) were 100% at 1 year and 83.3% at 5 years after LT. No significant differences were found among the survival rates of patients with or without SVR, probably due to the low number of investigated subjects.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Discussion</span><p id="p0080" class="elsevierStylePara elsevierViewall">End stage HCV-related liver cirrhosis is the most common indication for LT in Europe.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> However, HCV reinfection of the graft occurs almost universally, leading to graft cirrhosis within 5 years after LT in 10-30% of recipients and to an impaired survival.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> At present, the gold-standard of antiviral therapy is the combination of PEG-IFN plus ribavirin, administered, in most centres, after the histological diagnosis of infection recurrence in the graft. However, the reported SVR rates that could be achieved with the combined treatment are significantly lower than 50%, least of all in genotype 1 patients.<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">24</span></a><span class="elsevierStyleSup">–</span><a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p><p id="p0085" class="elsevierStylePara elsevierViewall">Similarly to immunocompetent subjects with chronic hepatitis C, SVR rates in transplanted patients are significantly lower in genotypes 1 and 4 (25-40%) than in genotypes 2 and 3 (53-76%).<a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">24</span></a><span class="elsevierStyleSup">–</span><a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> Despite the increasing diffusion of genotype 4 HCV in the Mediterranean countries, only a few data about its response to antiviral treatment after LT are available so far.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Selzner, <span class="elsevierStyleItalic">et al.</span><a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> treated with conventional or PEG-IFN 119 patients with genotype 1 and 4 recurrent hepatitis C after LT; SVR was achieved in 40% of cases but no data about the response of the 9 patients with genotype 4 HCV infection were reported. Similarly, Jimenez-Perez, <span class="elsevierStyleItalic">et al.</span><a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">30</span></a> reported a 41% rate of SVR in 41 patients transplanted for recurrent hepatitis C; only in 4 cases graft reinfection was due to HCV genotype 4, but no data about their response to treatment were provided. The only available literature series specifically concerning transplanted patients with recurrent genotype 4 chronic hepatitis C is those published by Mudawi, <span class="elsevierStyleItalic">et al.</span>,<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">31</span></a> who treated 17 patients from Saudi Arabia with a 48-week course of PEG-IFN alpha 2a plus ribavirin, achieving a SVR in 7 of them (41%) and Al-Hamoudi, <span class="elsevierStyleItalic">et al.</span>,<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">32</span></a> who treated 25 patients from Saudi Arabia with a 48-week course of PEGIFN alpha 2a plus ribavirin, achieving a SVR in 14 of them (56%).</p><p id="p0090" class="elsevierStylePara elsevierViewall">Therefore, our study, despite the small number of enrolled patients, represents to our knowledge the largest available series in Europe regarding post-LT genotype 4 recurrent hepatitis C antiviral treatment.</p><p id="p0095" class="elsevierStylePara elsevierViewall">According to the rates reported in patients with genotype 1, a SVR was achieved in 35.3% of our patients with recurrent genotype 4 chronic hepatitis C. Overall, EVR was able to predict the occurrence of SVR (p < 0.05) in 80% of patients with more than 24 weeks of therapy, while, in absence of EVR, a SVR was achieved only in one case. The SVR rate reported by our study is lower than that reported by Al-Hamoudi, <span class="elsevierStyleItalic">et al.</span>,<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> mainly because the authors excluded difficult-to-treat patients (those who failed previous pre-or post-transplant treatment, with renal failure, and pretreatment cytopenia), reporting only one case of treatment withdrawal. Moreover, in immunocompetent patients, Egyptian origin has been reported to be associated to higher SVR probabilties. Although the number of our transplanted patients is too low to draw any firm conclusion, we were not able to find a statistical difference (Chi-square 0.07; 1 d.f.) between SVR rates among Egyptian patients (40%) and the Italian ones (33.3%) (<a class="elsevierStyleCrossRef" href="#t0005">Table 1</a>).</p><p id="p0100" class="elsevierStylePara elsevierViewall">It is well known that, in immunocompetent subjects with genotype 1 chronic hepatitis C, the absence of EVR is a very strong predictor of treatment failure, since more than 90% of patients who do not reach EVR fail to achieve SVR.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">33</span></a> Some recent papers confirmed the relevance of EVR in predicting a subsequent SVR also in transplanted patients undergoing antiviral treatment for recurrent hepatitis C, mostly genotype 1-related.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a> Al-Hamoudi, <span class="elsevierStyleItalic">et al.</span><a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">3</span></a> also confirmed that the probability of achieving SVR was related to achieving a negative HCV RNA at week 12. Our experience supports this evidence also in genotype 4 transplanted patients; the-refore, in the subgroup of genotype 4 patients treated after liver transplantation who do not achieve an EVR, treatment discontinuation may be considered.</p><p id="p0105" class="elsevierStylePara elsevierViewall">Literature data highlight that, independently from HCV genotype, the achievement of SVR seems to improve significantly the long term survival of patients with post-LT recurrent hepatitis C undergoing antiviral treatment.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a><span class="elsevierStyleSup">,</span><a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">34</span></a> However, our series cannot support these data, since we were not able to find a statistical difference between the cumulative survival of subjects with or without SVR, probably due to the relatively low number of investigated patients. Furthermore, we included in our retrospective multicentric series only genotype 4 patients who were treated for HCV gen 4 recurrence after liver transplantation. Unfortunately, due to the study design, we were not able to collect data about those patients who did not receive the treatment, either due to mild hepatitis C recurrence or to contraindications to combined antiviral treatment. Therefore, we cannot provide any comparison regarding survival of these two groups.</p><p id="p0110" class="elsevierStylePara elsevierViewall">As a last consideration, a recent meta-analysis reported that more than 84% of Egyptians with HCC are positive for genotype 4 HCV.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">35</span></a> In our series, HCC was diagnosed in five patients (29.4%) and three of them were Egyptians. Then, HCC was present in 3 out of 5 Egyptian patients (60%) and in only 2 out of 12 Caucasians (16.7%). In particular, one of the 5 patients with HCC achieved a SVR but died 8 months after the end of the antiviral treatment due to HCC recurrence. However, in the other 4 cases, no HCC recurrence was observed. However, the small number of patients included in our retrospective series does not allow us to draw any epidemiologic conclusion.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Conclusion</span><p id="p0115" class="elsevierStylePara elsevierViewall">In conclusion, our study shows that transplanted patients with genotype 4 recurrent hepatitis C undergoing antiviral treatment achieve SVR in about one third of cases, and that EVR is a strong predictor of subsequent SVR.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:8 [ 0 => array:3 [ "identificador" => "xres1205126" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abs0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1122650" "titulo" => "Key words" ] 2 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 3 => array:2 [ "identificador" => "sec0010" "titulo" => "Material and Methods" ] 4 => array:2 [ "identificador" => "sec0015" "titulo" => "Results" ] 5 => array:2 [ "identificador" => "sec0020" "titulo" => "Discussion" ] 6 => array:2 [ "identificador" => "sec0025" "titulo" => "Conclusion" ] 7 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec1122650" "palabras" => array:5 [ 0 => "HCV recurrence" 1 => "Liver transplantation" 2 => "HCV treatment" 3 => "Genotype 4" 4 => "EVR" ] ] ] ] "tieneResumen" => true "resumen" => array:1 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abs0005" class="elsevierStyleSection elsevierViewall"><p id="sp0010" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Introduction.</span> Hepatitis C virus genotype 4 is predominant in the Middle East and Northern Africa, even if it has recently spread to Southern Europe. Data about the treatment of post-liver transplantation (LT) genotype 4 hepatitis C recurrence are scarce. We report a retrospective analysis of post-LT genotype 4 hepatitis C treatment in 9 Italian transplant centres, focusing on the overall survival rates and treatment outcome.</p><p id="sp0215" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Results.</span> Among 452 recipients, we identified 17 HCV genotype 4 patients (16 males, 1 female) transplanted between 1998 and 2007. All patients received combined antiviral treatment with conventional doses of interferon (recombinant or pegylated) and ribavirin after histological diagnosis of hepatitis C recurrence. The observed overall survival after LT was 100% at 1 year and 83.3% at 5 years. More than 1/3 (35.3%) of patients achieved a sustained virological response (SVR) and 40% (data available in 15 subjects) an early virological response (EVR), which was significantly associated with the achievement of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square p < 0.05).</p><p id="sp1015" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleBold">Conclusion.</span> In conclusion, in post-LT genotype 4 hepatitis C treatment, SVR rates are similar to genotype 1. Patients who don’t show an EVR are not likely to achieve a SVR.</p></span>" ] ] "NotaPie" => array:2 [ 0 => array:3 [ "etiqueta" => "*" "nota" => "<p class="elsevierStyleNotepara" id="npara0005">Non-Pegylated IFN.</p>" "identificador" => "fn0005" ] 1 => array:3 [ "etiqueta" => "†" "nota" => "<p class="elsevierStyleNotepara" id="npara0215">According to Ishak score. M: male. F: female. Eg: Egyptian. Ca: Caucasian. HCC: hepatocellular carcinoma. EVR: early virologic response. SVR: sustained virologic response.</p>" "identificador" => "fn0010" ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "t0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "tabla" => array:2 [ "leyenda" => "<p id="sp0105" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleFootnote" id="fn0005"><span class="elsevierStyleLabel">*</span><p class="elsevierStyleNotepara" id="npara0005">Non-Pegylated IFN.</p></span><span class="elsevierStyleFootnote" id="fn0010"><span class="elsevierStyleLabel">†</span><p class="elsevierStyleNotepara" id="npara0215">According to Ishak score. M: male. F: female. Eg: Egyptian. Ca: Caucasian. HCC: hepatocellular carcinoma. EVR: early virologic response. SVR: sustained virologic response.</p></span></p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Pts \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Sex \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Etnicity \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Age at LT (years) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">HCC genotype \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">HCV \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Grading <a class="elsevierStyleCrossRef" href="#fn0010"><span class="elsevierStyleSup">†</span></a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Staging <a class="elsevierStyleCrossRef" href="#fn0010"><span class="elsevierStyleSup">†</span></a> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Pretreatment viremia (IU/mL) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">EVR \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">Treatment duration (weeks) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="middle" scope="col" style="border-bottom: 2px solid black">SVR \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Eg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4<a class="elsevierStyleCrossRef" href="#fn0005">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">52 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Eg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4<a class="elsevierStyleCrossRef" href="#fn0005">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">51 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Eg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4<a class="elsevierStyleCrossRef" href="#fn0005">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">48 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Eg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1.687 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">16<a class="elsevierStyleCrossRef" href="#fn0005">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4c/4d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">756.100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">48 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4a/4c \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6.990.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">480.089 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">132.045 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">52 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">54 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6.686.247 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4c/4d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6.400.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">44 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4c/4d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">2.860.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">48 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">F \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">52 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4c/4d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">563.000 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">41 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4c/4d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">234 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Eg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">102.424 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">52 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">29.264 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4d \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">961.538 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">36<a class="elsevierStyleCrossRef" href="#fn0005">*</a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">No \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="middle">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">M \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Ca \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">43 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">7.692.307 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">35 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="center" valign="middle">Yes \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2057786.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="sp0005" class="elsevierStyleSimplePara elsevierViewall">Demographic and clinical features of the 17 investigated patients.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bs0005" "bibliografiaReferencia" => array:35 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Viral heterogeneity of the hepatitis C virus." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Simmonds P." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "1999" "volumen" => "31" "paginaInicial" => "54" "paginaFinal" => "560" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10622561" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Simmonds P." 1 => "Buck J." 2 => "Combet C." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.20819" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2005" "volumen" => "42" "paginaInicial" => "962" "paginaFinal" => "973" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16149085" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis C genotype 4: what we know and what we don’t yet know." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Kamal S.M." 1 => "Imad A.N." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.22127" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2008" "volumen" => "47" "paginaInicial" => "1371" "paginaFinal" => "1383" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18240152" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of hepatitis C virus genotype 4: recommendations of an international expert panel." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Khattab M.A." 1 => "Ferenci P." 2 => "Hadziyannis S.J." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hepatology" "fecha" => "2011" "volumen" => "54" "paginaInicial" => "1250" "paginaFinal" => "1262" ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Ansaldi F." 1 => "Bruzzone B." 2 => "Salmaso S." 3 => "Rota M.C." 4 => "Durando P." 5 => "Gasparini R." 6 => "Icardi G." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/jmv.20376" "Revista" => array:6 [ "tituloSerie" => "J Med Virol" "fecha" => "2005" "volumen" => "76" "paginaInicial" => "327" "paginaFinal" => "332" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15902713" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Antaki N." 1 => "Craxi A." 2 => "Kamal S.M." 3 => "Moucari R." 4 => "Van der Merwe S." 5 => "Haffar S." 6 => "Gadano A." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Liver Int" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "335" "paginaFinal" => "342" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "El-Zayadi A." 1 => "Simmonds P." 2 => "Dabbous H." 3 => "Prescott L." 4 => "Selim O." 5 => "Ahdy A." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Viral Hepat" "fecha" => "1996" "volumen" => "3" "paginaInicial" => "261" "paginaFinal" => "264" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8914006" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "El-Zayadi A." 1 => "Selim O." 2 => "Haddad S." 3 => "Simmonds P." 4 => "Hamdy H." 5 => "Badran H.M." 6 => "Shawky S." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Gastroenterol Hepatol" "fecha" => "1999" "volumen" => "31" "paginaInicial" => "472" "paginaFinal" => "475" ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interferon therapy in patients with chronic hepatitis C and schistosomiasis." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Kamal S.M." 1 => "Madwar M.A." 2 => "Peters T." 3 => "Fawzy R." 4 => "Rasenack J." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2000" "volumen" => "32" "paginaInicial" => "172" "paginaFinal" => "174" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10673085" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of hepatitis C virus genotype 4-related cirrhosis: Ribavirin and interferon combination compared with interferon alone." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Koshy A." 1 => "Madda J.P." 2 => "Marcellin P." 3 => "Martinot M." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Clin Gastroenterol" "fecha" => "2002" "volumen" => "35" "paginaInicial" => "82" "paginaFinal" => "85" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12080232" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:10 [ 0 => "Alfaleh F.Z." 1 => "Hadad Q." 2 => "Khuroo M.S." 3 => "Aljumah A." 4 => "Algamedi A." 5 => "Alashgar H." 6 => "Al-Ahdal M.N." 7 => "Mayet I." 8 => "Khan M.Q." 9 => "Kessie G." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1478-3231.2004.0976.x" "Revista" => array:6 [ "tituloSerie" => "Liver Int" "fecha" => "2004" "volumen" => "24" "paginaInicial" => "568" "paginaFinal" => "574" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15566506" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:7 [ 0 => "Hasan F." 1 => "Asker H." 2 => "Al-Khaldi J." 3 => "Siddique I." 4 => "Al-Ajmi M." 5 => "Owaid S." 6 => "Varghese R." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1572-0241.2004.40077.x" "Revista" => array:6 [ "tituloSerie" => "Am J Gastroenterol" "fecha" => "2004" "volumen" => "99" "paginaInicial" => "1733" "paginaFinal" => "1737" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15330911" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Kamal S.M." 1 => "El Tawil A.A." 2 => "Nakano T." 3 => "He Q." 4 => "Rasenack J." 5 => "Hakam S.A." 6 => "Saleh W.A." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/gut.2004.057182" "Revista" => array:6 [ "tituloSerie" => "Gut" "fecha" => "2005" "volumen" => "54" "paginaInicial" => "858" "paginaFinal" => "866" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15888797" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pegylated interferon alpha-2b plus ribavirine in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Kamal S.M." 1 => "El Kamary S.S." 2 => "Shardell M.D." 3 => "Hashem M." 4 => "Ahmed I.N." 5 => "Muhammadi M." 6 => "Sayed K." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.21917" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "1732" "paginaFinal" => "1740" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17943989" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Roulot D." 1 => "Bourcier V." 2 => "Grando V." 3 => "Deny P." 4 => "Baazia Y." 5 => "Fontaine H." 6 => "Bailly F." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2893.2006.00823.x" "Revista" => array:6 [ "tituloSerie" => "J Viral Hepat" "fecha" => "2007" "volumen" => "14" "paginaInicial" => "460" "paginaFinal" => "467" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17576387" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "El Makhzangy H." 1 => "Esmat G." 2 => "Said M." 3 => "Elraziky M." 4 => "Shouman S." 5 => "Refai R." 6 => "Rekacewicz C." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J of Med Vir" "fecha" => "2009" "volumen" => "81" "paginaInicial" => "1576" "paginaFinal" => "1583" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:9 [ 0 => "Elefsiniotis I.S." 1 => "Pavlidis C." 2 => "Dimitroulopoulos D." 3 => "Vezali E." 4 => "Mihas C." 5 => "Mariolis-Sapsakos T." 6 => "Koutsounas S." 7 => "Paraskevas E." 8 => "Saroglou G." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2893.2009.01134.x" "Revista" => array:6 [ "tituloSerie" => "J Viral Hepat" "fecha" => "2009" "volumen" => "16" "paginaInicial" => "738" "paginaFinal" => "742" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19413697" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Manns M.P." 1 => "McHutchison J.G." 2 => "Gordon S.C." 3 => "Rustgi V.K." 4 => "Shiffman M." 5 => "Reindollar R." 6 => "Goodman Z.D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0140-6736(01)06102-5" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2001" "volumen" => "358" "paginaInicial" => "958" "paginaFinal" => "965" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11583749" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Fried M.W." 1 => "Shiffman M.L." 2 => "Reddy K.R." 3 => "Smith C." 4 => "Marinos G." 5 => "Goncales F.L. Jr." 6 => "Haussinger D." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa020047" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2002" "volumen" => "347" "paginaInicial" => "975" "paginaFinal" => "982" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12324553" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Ferenci P." 1 => "Laferl H." 2 => "Sherzer T.M." 3 => "Gschwantler M." 4 => "Maieron A." 5 => "Brunner H." 6 => "Stauber R." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2008.04.015" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2008" "volumen" => "135" "paginaInicial" => "451" "paginaFinal" => "458" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18503773" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Elefsiniotis I.S." 1 => "Vezali E." 2 => "Mihas C." 3 => "Saroglou G." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000228548" "Revista" => array:6 [ "tituloSerie" => "Intervirology" "fecha" => "2009" "volumen" => "52" "paginaInicial" => "247" "paginaFinal" => "251" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19602898" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Adam R." 1 => "McMaster P." 2 => "O’Grady J.G." 3 => "Castaing D." 4 => "Klempnauer J.L." 5 => "Jamieson N." 6 => "Neuhaus P." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Liver Transpl" "fecha" => "2009" "volumen" => "12" "paginaInicial" => "1231" "paginaFinal" => "1243" ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What determines the natural history of recurrent hepatitis C after liver transplantation?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Berenguer M." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2005.01.011" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2005" "volumen" => "42" "paginaInicial" => "448" "paginaFinal" => "456" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15763325" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Selzner N." 1 => "Renner E.L." 2 => "Selzner M." 3 => "Adeyi O." 4 => "Kashfi A." 5 => "Therapondos G." 6 => "Nigel Girgrah N." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/TP.0b013e3181bd783c" "Revista" => array:6 [ "tituloSerie" => "Transplantation" "fecha" => "2009" "volumen" => "88" "paginaInicial" => "1214" "paginaFinal" => "1221" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19935376" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical trial: peg-interferon alfa2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Lodato F." 1 => "Berardi S." 2 => "Gramenzi A." 3 => "Mazzella G." 4 => "Lenzi M." 5 => "Morelli M.C." 6 => "Tame M.R." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1365-2036.2008.03761.x" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2008" "volumen" => "28" "paginaInicial" => "450" "paginaFinal" => "457" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18549463" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0130" "etiqueta" => "26." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Cescon M." 1 => "Grazi G.L." 2 => "Cucchetti A." 3 => "Vetrone G." 4 => "Ravaioli M." 5 => "Ercolani G." 6 => "Morelli M.C." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/lt.21760" "Revista" => array:6 [ "tituloSerie" => "Liver Transpl" "fecha" => "2009" "volumen" => "15" "paginaInicial" => "782" "paginaFinal" => "789" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19562715" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0135" "etiqueta" => "27." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "Berenguer M." 1 => "Palau A." 2 => "Aguilera V." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1600-6143.2007.02126.x" "Revista" => array:6 [ "tituloSerie" => "Am J Transplant" "fecha" => "2008" "volumen" => "8" "paginaInicial" => "679" "paginaFinal" => "687" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18294165" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0140" "etiqueta" => "28." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Berenguer M." 1 => "Aguilera V." 2 => "Prieto M." 3 => "Rayón J.M." 4 => "Juan F.S." 5 => "Prieto M." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/lt.21707" "Revista" => array:6 [ "tituloSerie" => "Liver Transpl" "fecha" => "2009" "volumen" => "15" "paginaInicial" => "738" "paginaFinal" => "746" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19562707" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0145" "etiqueta" => "29." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Swiss Association for the Study of the Liver (SASL 17). Pegylated interferonalpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:9 [ 0 => "Dinges S." 1 => "Morard I." 2 => "Heim M." 3 => "Dufour J.F." 4 => "Müllhaupt B." 5 => "Giostra E." 6 => "Clavien P.A." 7 => "Mentha G." 8 => "Negro F." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1399-3062.2008.00359.x" "Revista" => array:6 [ "tituloSerie" => "Transpl Infect Dis" "fecha" => "2009" "volumen" => "11" "paginaInicial" => "33" "paginaFinal" => "39" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19144096" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0150" "etiqueta" => "30." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Jiménez-Pérez M." 1 => "Sáez-Gómez A.B." 2 => "Pérez-Daga J.A." 3 => "Lozano-Rey J.M." 4 => "De la Cruz-Lombardo J." 5 => "Rodrigo-López J.M." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.transproceed.2010.02.008" "Revista" => array:6 [ "tituloSerie" => "Transplant Proc" "fecha" => "2010" "volumen" => "42" "paginaInicial" => "666" "paginaFinal" => "668" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20304219" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0155" "etiqueta" => "31." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation: Natural history and predictors of outcome." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Mudawi H." 1 => "Helmy A." 2 => "Kamel Y." 3 => "Al Saghier M." 4 => "Al Sofayan M." 5 => "Al Sebayel M." 6 => "Khalaf H." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4103/0256-4947.51796" "Revista" => array:6 [ "tituloSerie" => "Ann Saudi Med" "fecha" => "2009" "volumen" => "29" "paginaInicial" => "91" "paginaFinal" => "97" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19318754" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0160" "etiqueta" => "32." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Al-Hamoudi W." 1 => "Mohamed H." 2 => "Abaalkhail F." 3 => "Kamel Y." 4 => "Al-Masri N." 5 => "Allam N." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10620-010-1526-5" "Revista" => array:6 [ "tituloSerie" => "Dig Dis Sci" "fecha" => "2011" "volumen" => "56" "paginaInicial" => "1848" "paginaFinal" => "1852" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21221800" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0165" "etiqueta" => "33." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diagnosis, management, and treatment of hepatitis C: an update." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Ghany M.G." 1 => "Strader D.B." 2 => "Thomas D.L." 3 => "Seeff L.B." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.22759" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2009" "volumen" => "49" "paginaInicial" => "1335" "paginaFinal" => "1374" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19330875" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0170" "etiqueta" => "34." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation." "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "Picciotto F.P." 1 => "Tritto G." 2 => "Lanza A.G." 3 => "Addario L." 4 => "De Luca M." 5 => "Di Costanzo G.G." 6 => "Lampasi F." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2006.10.017" "Revista" => array:6 [ "tituloSerie" => "J Hepatol" "fecha" => "2007" "volumen" => "46" "paginaInicial" => "459" "paginaFinal" => "465" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17196700" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0175" "etiqueta" => "35." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis." "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Lehman E.M." 1 => "Wilson M.L." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/ijc.23937" "Revista" => array:6 [ "tituloSerie" => "Int J Cancer" "fecha" => "2009" "volumen" => "124" "paginaInicial" => "690" "paginaFinal" => "697" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18973270" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000001100000003/v1_201906130956/S1665268119309299/v1_201906130956/en/main.assets" "Apartado" => array:4 [ "identificador" => "77721" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Article" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000001100000003/v1_201906130956/S1665268119309299/v1_201906130956/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268119309299?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 October | 5 | 5 | 10 |
2024 September | 28 | 15 | 43 |
2024 August | 16 | 7 | 23 |
2024 July | 15 | 3 | 18 |
2024 June | 8 | 3 | 11 |
2024 May | 7 | 6 | 13 |
2024 April | 17 | 2 | 19 |
2024 March | 13 | 5 | 18 |
2024 February | 11 | 5 | 16 |
2024 January | 9 | 28 | 37 |
2023 December | 12 | 24 | 36 |
2023 November | 10 | 21 | 31 |
2023 October | 15 | 33 | 48 |
2023 September | 12 | 18 | 30 |
2023 August | 16 | 23 | 39 |
2023 July | 3 | 22 | 25 |
2023 June | 4 | 10 | 14 |
2023 May | 5 | 0 | 5 |
2023 April | 5 | 4 | 9 |
2023 March | 2 | 3 | 5 |
2023 February | 4 | 6 | 10 |
2023 January | 13 | 15 | 28 |
2022 December | 9 | 3 | 12 |
2022 November | 16 | 11 | 27 |
2022 October | 7 | 4 | 11 |
2022 September | 8 | 6 | 14 |
2022 August | 5 | 5 | 10 |
2022 July | 7 | 8 | 15 |
2022 June | 5 | 6 | 11 |
2022 May | 13 | 7 | 20 |
2022 April | 8 | 10 | 18 |
2022 March | 4 | 6 | 10 |
2022 February | 4 | 3 | 7 |
2022 January | 12 | 4 | 16 |
2021 December | 4 | 8 | 12 |
2021 November | 2 | 6 | 8 |
2021 October | 9 | 10 | 19 |
2021 September | 7 | 9 | 16 |
2021 August | 9 | 4 | 13 |
2021 July | 6 | 7 | 13 |
2021 June | 8 | 3 | 11 |
2021 May | 10 | 9 | 19 |
2021 April | 24 | 5 | 29 |
2021 March | 7 | 5 | 12 |
2021 February | 6 | 4 | 10 |
2021 January | 5 | 4 | 9 |
2020 December | 7 | 6 | 13 |
2020 November | 4 | 10 | 14 |
2020 October | 3 | 4 | 7 |
2020 September | 6 | 5 | 11 |
2020 August | 4 | 0 | 4 |
2020 July | 4 | 0 | 4 |
2020 June | 3 | 1 | 4 |
2020 May | 3 | 5 | 8 |
2020 April | 0 | 2 | 2 |
2020 March | 6 | 7 | 13 |
2020 February | 1 | 3 | 4 |
2020 January | 3 | 7 | 10 |
2019 December | 8 | 5 | 13 |
2019 November | 4 | 1 | 5 |
2019 October | 0 | 1 | 1 |
2019 September | 2 | 5 | 7 |
2019 August | 3 | 1 | 4 |
2019 July | 0 | 7 | 7 |
2019 June | 3 | 7 | 10 |